Granted Patent
B2
US 12,403,155 · App. 18/055,525 · Granted Sep 2, 2025
Methods and compositions for the activation of gamma-delta T-cells
Inventors:
Charles David Pauza (Rockville, MD); Haishan Li (Rockville, MD); Tyler Lahusen (Rockville, MD); Mei-Ling Liou (Rockville, MD)
A61K31/7105A61K31/675A61K47/6807A61K47/6901A61P35/02C12N15/1137C12N15/86C12Y205/0101A61K2300/00C12N2310/14C12N2310/531C12N2330/51C12N2740/16032C12N2740/16043C12N2740/16045C12N2750/14143C12N2810/6072
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention relates generally to methods and compositions for gene therapy and immunotherapy that activate gamma delta T-cells, and in particular, can be used in the treatment of various cancers and infectious diseases.
Claims (37)
1. A pharmaceutical combination, comprising:
(a) a bisphosphonate drug; and
(b) a lentiviral particle comprising an envelope protein and a therapeutic vector comprising:
an EF-1 alpha promoter and
at least one encoded shRNA or microRNA that, when expressed, inhibits production of farnesyl diphosphate synthase (FDPS)
wherein the bisphosphonate drug and lentiviral particle are administered together or separately,
wherein the at least one encoded shRNA or microRNA comprises a sequence having at least 80 percent identity with SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, or SEQ ID NO: 10.
2. The pharmaceutical combination of claim 1 , wherein the at least one encoded shRNA or microRNA activates a GD T cell.
3. The pharmaceutical combination of claim 1 , wherein the at least one encoded shRNA or microRNA activates a GD T cell.
4. The pharmaceutical combination of claim 1 , wherein the envelope protein is capable of infecting a cancer cell.
5. The pharmaceutical combination of claim 1 , wherein the bisphosphonate drug comprises zoledronic acid.
6. A pharmaceutical combination, comprising:
(a) a bisphosphonate drug; and
(b) a lentiviral particle comprising an envelope protein and a therapeutic vector comprising:
at least one encoded shRNA or microRNA that, when expressed, inhibits production of farnesyl diphosphate synthase (FDPS) and activates a GD T cell wherein the bisphosphonate drug and lentiviral particle are administered together or separately,
wherein the at least one encoded shRNA or microRNA comprises a sequence having at least 80 percent identity with SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, or SEQ ID NO: 10.
7. The pharmaceutical combination of claim 6 , wherein the envelope protein is capable of infecting a cancer cell.
8. The pharmaceutical combination of claim 6 , wherein the bisphosphonate drug comprises zoledronic acid.
9. A method of treating a cancer in a subject in need thereof, using an immunotherapy-based composition, the method comprising:
(a) administering a therapeutically-effective amount of an bisphosphonate drug to the subject; and
(b) administering a therapeutically-effective amount of the immunotherapy-based composition to the subject,
wherein the immunotherapy-based composition comprises a lentiviral particle, the lentiviral particle comprising an envelope protein and a therapeutic vector comprising:
an EF-1 alpha promoter; and,
at least one encoded shRNA or microRNA that, when expressed, inhibits production of farnesyl diphosphate synthase (FDPS),
wherein the at least one encoded shRNA or microRNA comprises a sequence having at least 80 percent identity with SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, or SEQ ID NO: 10.
10. The method of claim 9 , wherein the at least one encoded shRNA or microRNA activates a GD T cell.
11. The method of claim 9 , wherein the at least one encoded shRNA or microRNA activates a GD T cell.
12. The method of claim 9 , wherein the cancer is selected from one or more of a carcinoma, a leukemia, a lymphoma, a sarcoma, a myeloma, a mesothelioma, a mixed type, or mixtures thereof.
13. The method of claim 9 , wherein the bisphosphonate drug comprises zoledronic acid.
14. A method of treating a cancer in a subject in need thereof, using an immunotherapy-based composition, the method comprising:
(a) administering a therapeutically-effective amount of an bisphosphonate drug to the subject; and
(b) administering a therapeutically-effective amount of the immunotherapy-based composition to the subject,
wherein the immunotherapy-based composition comprises a lentiviral particle, the lentiviral particle comprising an envelope protein and a therapeutic vector comprising:
at least one encoded shRNA or microRNA that, when expressed, inhibits production of farnesyl diphosphate synthase (FDPS) and activates a GD T cell,
wherein the at least one encoded shRNA or microRNA comprises a sequence having at least 80 percent identity with SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, or SEQ ID NO: 10.
15. The method of claim 14 , wherein the cancer is selected from one or more of a carcinoma, a leukemia, a lymphoma, a sarcoma, a myeloma, a mesothelioma, a mixed type, or mixtures thereof.
16. The method of claim 14 , wherein the bisphosphonate drug comprises zoledronic acid.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Nov 15, 2022
From: PAUZA, CHARLES DAVID; LI, HAISHAN; LAHUSEN, TYLER; LIOU, MEI-LING
To: AMERICAN GENE TECHNOLOGIES INTERNATIONAL INC.
Reel/Frame 061772/0167 →
Continuity (8)
Continuation
PCTUS2017013399
· Jan 13, 2017
Provisional Application
62279474
· Jan 15, 2016
References Cited (332)
US 5668255A
· Murphy
· 1997
[cited by applicant]
US 8124752B2
· Bumcrot et al.
· 2012
[cited by applicant]
US 8287857B2
· Dudley et al.
· 2012
[cited by applicant]
US 8993532B2
· Hannon et al.
· 2015
[cited by applicant]
US 9522176B2
· DeRosa et al.
· 2016
[cited by applicant]
US 9834790B1
· Pauza et al.
· 2017
[cited by applicant]
US 9914938B2
· Pauza et al.
· 2018
[cited by applicant]
US 20040142416A1
· Laipis et al.
· 2004
[cited by applicant]
US 20040192629A1
· Xu et al.
· 2004
[cited by applicant]
US 20040248296A1
· Beresford et al.
· 2004
[cited by applicant]
US 20050019927A1
· Markus et al.
· 2005
[cited by applicant]
US 20050138677A1
· Pfister et al.
· 2005
[cited by applicant]
US 20060057553A1
· Aguilar-Cordova
· 2006
[cited by applicant]
US 20060246520A1
· Champagne et al.
· 2006
[cited by applicant]
US 20080003225A1
· Vie et al.
· 2008
[cited by applicant]
US 20080199961A1
· Rasko et al.
· 2008
[cited by applicant]
US 20080227736A1
· Chen et al.
· 2008
[cited by applicant]
US 20080293142A1
· Liu et al.
· 2008
[cited by applicant]
US 20090148936A1
· Stout et al.
· 2009
[cited by applicant]
US 20090304688A1
· Fournie et al.
· 2009
[cited by applicant]
US 20120027725A1
· Galvin et al.
· 2012
[cited by applicant]
US 20130090371A1
· Lu
· 2013
[cited by applicant]
US 20140348794A1
· Chiorini et al.
· 2014
[cited by applicant]
US 20150018539A1
· Fellmann
· 2015
[cited by applicant]
US 20160060707A1
· Goldenberg et al.
· 2016
[cited by applicant]
US 20160243169A1
· Chen et al.
· 2016
[cited by applicant]
US 20160287635A1
· Hariri et al.
· 2016
[cited by applicant]
US 20170015976A1
· Nelson
· 2017
[cited by applicant]
US 20200318081A1
· Lahusen et al.
· 2020
[cited by applicant]
CN 101516365A
· 2009
[cited by applicant]
CN 101679466A
· 2010
[cited by applicant]
CN 101805750A
· 2010
[cited by applicant]
CN 105112370A
· 2015
[cited by applicant]
CN 108883100A
· 2018
[cited by applicant]
EP 3402483A1
· 2018
[cited by applicant]
EP 3426777A2
· 2019
[cited by applicant]
JP 2007527240A
· 2007
[cited by applicant]
JP 2008538174A
· 2008
[cited by applicant]
JP 2013530152A
· 2013
[cited by applicant]
JP 2015518838A
· 2015
[cited by applicant]
JP 2016502404A
· 2016
[cited by applicant]
WO WO2002020554
· 2002
[cited by applicant]
WO WO2003093436
· 2003
[cited by applicant]
WO WO2005033282
· 2005
[cited by applicant]
WO WO2006039721A2
· 2006
[cited by applicant]
WO WO2006089001A2
· 2006
[cited by applicant]
WO WO2007000668
· 2007
[cited by applicant]
WO WO2007015122A1
· 2007
[cited by applicant]
WO WO2007132292A2
· 2007
[cited by applicant]
WO WO2008025025A2
· 2008
[cited by applicant]
WO WO2009001224A2
· 2008
[cited by applicant]
WO WO2009100928
· 2009
[cited by applicant]
WO WO2009147445
· 2009
[cited by applicant]
WO WO2010051521
· 2010
[cited by applicant]
WO WO2010111522A2
· 2010
[cited by applicant]
WO WO2010117974
· 2010
[cited by applicant]
WO WO2010119039A1
· 2010
[cited by applicant]
WO WO2010127166
· 2010
[cited by applicant]
WO WO2011008348
· 2011
[cited by applicant]
WO WO2011148194A1
· 2011
[cited by applicant]
WO WO2012048303A2
· 2012
[cited by applicant]
WO WO2012061075
· 2012
[cited by applicant]
WO WO2012071559A2
· 2012
[cited by applicant]
WO WO2012145624A2
· 2012
[cited by applicant]
WO WO2013056148A2
· 2013
[cited by applicant]
WO WO2013096455A1
· 2013
[cited by applicant]
WO WO2014117050A2
· 2014
[cited by applicant]
WO WO2014187881
· 2014
[cited by applicant]
WO WO2014195159A1
· 2014
[cited by applicant]
WO WO2015017755A1
· 2015
[cited by applicant]
WO WO2015061491
· 2015
[cited by applicant]
WO WO2015078999
· 2015
[cited by applicant]
WO WO2015164759A2
· 2015
[cited by applicant]
WO WO2016046234
· 2016
[cited by applicant]
WO WO2016122058
· 2016
[cited by applicant]
WO WO2017068077A1
· 2017
[cited by applicant]
WO WO2017100551
· 2017
[cited by applicant]
WO WO2017123918A1
· 2017
[cited by applicant]
WO WO2017156311A2
· 2017
[cited by applicant]
WO WO2017165641A1
· 2017
[cited by applicant]
WO WO2017173453A1
· 2017
[cited by applicant]
WO WO2018126112
· 2018
[cited by applicant]
WO WO2018148443A1
· 2018
[cited by applicant]
WO WO2018187231
· 2018
[cited by applicant]
WO WO2018232359A1
· 2018
[cited by applicant]
WO WO2019070674
· 2019
[cited by applicant]
WO WO2020011247A1
· 2020
[cited by applicant]
WO WO2020097049A1
· 2020
[cited by applicant]
WO WO2020243717
· 2020
[cited by applicant]
Nielson et al., Molecular Therapy vol. 15, Suppl. 1:S270, May 2007.
[cited by examiner]
JP Office Action in Japanese Application No. 2022-006999, dated Jan. 5, 2023, 20 pages (with English translation).
[cited by applicant]
IL Office Action issued in Application No. 271274 on Aug. 6, 2023, 11 pages.
[cited by applicant]
JP; Office Action issued in Application No. 2022-006999 on Sep. 20, 2023.
[cited by applicant]
USPTO; Examiner's Answer in U.S. Appl. No. 16/614,682, dated Sep. 27, 2023.
[cited by applicant]
Brake et al., “Lentiviral Vector Design for Multiple shRNA Expression and Durable HIV-1 Inhibition,” Molecular Therapy, 16(3), 557-564, 2008.
[cited by applicant]
KR; Office Action issued Oct. 20, 2023 in Application No. 10-2020-7000631.
[cited by applicant]
UAE; Office Action issued Oct. 20, 2023 in Application No. P6001801/2019.
[cited by applicant]
JP; Office Action issued Oct. 19, 2023 in Application No. 2021-523916.
[cited by applicant]
US; Restriction Requirement issued in U.S. Appl. No. 17/570,313 on Nov. 15, 2023.
[cited by applicant]
CN; Office Action issued in Application No. 201880039828.4 on Nov. 30, 2023.
[cited by applicant]
IL; Notice of Allowance issued in Application No. 297238 on Dec. 11, 2023.
[cited by applicant]
Altschul S.F., et al., “Basic Local Alignment Search Tool,” Journal Molecular Biology, 1990, vol. 215, pp. 403-410.
[cited by applicant]
Altschul S.F., et al., “Gapped BLAST and PSI-BLAST: A New Generation of Protein Database Search Programs,” Nucleic Acids Research, Jul. 1997, vol. 25, No. 17, pp. 3389-3402.
[cited by applicant]
Ausubel F.M., et al., “Short Protocols in Molecular Biology: A Compendium of Methods from Current Protocols in Molecular Biology,” Wiley, John & Sons, Inc., 1995, 1 Page.
[cited by applicant]
Benyamine A., et al., “BTN3A Molecules Considerably Improve Vy9Vδ2T Cells-based Immunotherapy in Acute Myeloid Leukemia,” Oncolmmunology, Oct. 2, 2016, vol. 5, No. 10, 10 Pages, (E1146843) *the whole document*.
[cited by applicant]
Berge et al., “Pharmaceutical Salts” Jan. 1977, Journal of Pharmaceutical Sciences, 66(1):1-19.
[cited by applicant]
Capietto A-H., et al., “Stimulated Yδ T Cells Increase the in Vivo Efficacy of Trastuzumab in HER-2+ Breast Cancer,” Journal of Immunology, 2011, vol. 187(2), pp. 1031-1038.
[cited by applicant]
Chen H.C., et al., “An Unconventional TRAIL to Cancer Therapy,” European Journal of Immunology, 2013, vol. 43, No. 12, pp. 3159-3162, DOI:10.1002/eji.201344105, ISSN 0004789814, XP071226184.
[cited by applicant]
Chen Z., et al., “CD16+ Gammadelta T Cells Mediate Antibody Dependent Cellular Cytotoxicity: Potential Mechanism In The Pathogenesis Of Multiple Sclerosis,” Clinical Immunology, 2008, vol. 128(2), pp. 219-227.
[cited by applicant]
Cheng M., et al., “Establishment, Characterization, and Successful Adaptive Therapy Against Human Tumors of NKG Cell, a New Human NK Cell Line”, Cell Transplantation, Jun. 2011, vol. 20, pp. 1731-1746.
[cited by applicant]
Coligan J.E., et al., “Current Protocols in Protein Science,” Short Protocols in Protein Science, 1996, vol. 24, No. 409, 1 Page.
[cited by applicant]
Corrected Notice of Allowance for U.S. Appl. No. 16/563,738, mailed Aug. 31, 2022,5 Pages.
[cited by applicant]
Couzi L., et al., “Antibody-Dependent Anti-Cytomegalovirus Activity of Human Gammadelta T Cells Expressing CD16 (FcgammaRIIIa),” Blood, 2012, vol. 119(6), pp. 1418-1427.
[cited by applicant]
Davis-Gardner M.E., et al., “eCD4-Ig promotes ADCC activity of sera from HIV-1-infected patients”, Department of Immunology and Microbiology, The Scripps Research Institute, PLOS Pathogen, Dec. 18, 2017, 19 Pages, Retri…
[cited by applicant]
Deveraux J., et al., “A Comprehensive Set of Sequence Analysis Programs for the VAX,” Nucleic Acids Research, 1984, vol. 12, No. 1, pp. 387-395.
[cited by applicant]
Dieli F., et al., “Targeting Human γδT Cells with Zoledronate and Interleukin-2 for Immunotherapy of Hormone-Refractory Prostate Cancer,” Europe PMC Funders Group, Cancer Research, Aug. 1, 2007, vol. 67, No. 15, pp. 745…
[cited by applicant]
Extended European Search Report for European Application No. 19883230.5, mailed Jul. 21, 2022, 9 Pages.
[cited by applicant]
Extended European Search Report for European Application No. 17764128.9, mailed Aug. 12, 2019, 8 Pages.
[cited by applicant]
Extended European Search Report for European Application No. 18817253.0, mailed Feb. 10, 2021,8 Pages.
[cited by applicant]
Extended European Search Report for European Application No. 22154806.8, mailed Jul. 4, 2022, 8 Pages.
[cited by applicant]
Extended European Search Report for European Application No. 17739028.3, mailed Jun. 6, 2019, 8 Pages.
[cited by applicant]
Final Office Action for U.S. Appl. No. 16/132,247, mailed Jul. 1, 2019, 7 Pages.
[cited by applicant]
Final Office Action for U.S. Appl. No. 16/182,443, mailed May 2, 2019, 07 Pages.
[cited by applicant]
Final Office Action for U.S. Appl. No. 16/614,682, mailed Aug. 2, 2022, 34 Pages.
[cited by applicant]
First Office Action in the CN Application No. 201780017712.6, mailed May 8, 2020, 10 Pages.
[cited by applicant]
Fisher J.P.H., et al., “Effective Combination Treatment of GD2-Expressing Neuroblastoma and Ewing's Sarcoma Using Anti-GD2 ch14.18/CHO Antibody with Vy9V52+ yT Cells,” Oncolmmunology, 2016, vol. 5, Issue No. 1, e1025194…
[cited by applicant]
Fujiwara Y., et al., “A Nucleolar Stress-Specific p53-miR-101 Molecular Circuit Functions as an Intrinsic Tumor-Suppressor Network,” EBiomedicine, NL, Jul. 7, 2018, vol. 33, pp. 33-48, DOI: 10.1016/j.ebiom.2018.06.031, …
[cited by applicant]
Gagniuc P., et al., “Eukaryotic Genomes May Exhibit up to 10 Generic Classes of Gene Promoters,” Bmc Genomics, 2012, vol. 13, 17 Pages, DOI:10.1186/1471-2164-13-512, XP021134695.
[cited by applicant]
Gennaro A.R., “Remington's Pharmaceutical Sciences,” 17th edition, Mack Publishing Company, Easton, Pa., Oct. 1985, vol. 74, No. 10, pp. 1143-1144.
[cited by applicant]
Gertner-Dardenne J., et al., “Bromohydrin Pyrophosphate Enhances Antibody-Dependent Cell-Mediated Cytotoxicity Induced by Therapeutic Antibodies,” Blood, 2009, vol. 113(20), pp. 4875-4884.
[cited by applicant]
Harlow E., et al., “Antibodies: A Laboratory Manual,” Cold Spring Harbor Laboratory Press, 1988, 1 Page.
[cited by applicant]
Harly C., et al., “Key Implication of CD277/butyrophilin-3 (BTN3A) in Cellular Stress Sensing by a Major Human T-cell Subset,” Blood, Sep. 13, 2012, vol. 120, No. 11, pp. 2269-2279, DOI:10.1182/blood-2012-05-430470, ISS…
[cited by applicant]
Hassan G., et al., “Isolation of Umbilical Cord Mesenchymal Stem Cells Using Human Blood Derivative Accompanied With Explant Method,” Stem Cell Investigation, 2019, pp. 1-8.
[cited by applicant]
Herrera L., et al., “Adult Peripheral Blood and Umbilical Cord Blood NK Cells Are Good Sources for Effective CAR Therapy Against CD19 Positive Leukemic Cells,” Scientific Reports, Dec. 2019, vol. 9, Article. 18729, 2 Pa…
[cited by applicant]
Huang Q., et al., “An Efficient Protocol to Generate Placental Chorionic Plate-derived Mesenchymal Stem Cells with Superior Proliferative and Immunomodulatory Properties,” Stem Cell Research & Therapy, 2019, vol. 10(301…
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2021/020721, mailed Jul. 21, 2021, 10 Pages.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2019/059828, mailed Feb. 14, 2020, 12 Pages.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2022/013422, mailed May 13, 2022, 19 Pages.
[cited by applicant]
International Search Report for International Application No. PCT/US2017/013399, mailed May 26, 2017, 4 Pages.
[cited by applicant]
International Search Report for International Application No. PCT/US2017/021639, mailed Aug. 25, 2017, 5 Pages.
[cited by applicant]
International Search Report for International Application No. PCT/US2018/037924, mailed Nov. 9, 2018, 7 Pages.
[cited by applicant]
Invitation to Pay Additional Fees and, where Applicable, Protest Fee for International Application No. PCT/US2018/037924, mailed Sep. 11, 2018, 3 Pages.
[cited by applicant]
Jiang X., et al., “A Novel EST-derived RNAi Screen Reveals a Critical Role For Farnesyl Diphosphate Synthase in Beta 2-adrenergic Receptor Internalization and Down-regulation,” The FASEB Journal, Published Online on Jan…
[cited by applicant]
Li J., et al., “Reduced Expression of the Mevalonate Pathway Enzyme Farnesyl Pyrophosphate Synthase Unveils Recognition of Tumor Cells by V[gamma]9V[delta]2 T Cells,” The Journal of Immunology, US, (Jun. 3, 2009), Jun. …
[cited by applicant]
Li Z., et al., “Inhibition of Farnesyl Pyrophosphate Synthase Prevents Angiotensin II-induced Cardiac Fibrosis In Vitro,” Clinical & Experimental Immunology, 2014, vol. 176, pp. 429-437.
[cited by applicant]
Mensali N., et al., “NK Cells Specifically TCR-dressed to Kill Cancer Cells”, EBioMedicine, Jan. 2019, vol. 40, pp. 106-117.
[cited by applicant]
Miettinen T.P., et al., “Mevalonate Pathway Regulates Cell Size Homeostasis and Proteostasis Through Autophagy,” Cell Reports, Dec. 22, 2015, vol. 13(11), pp. 2610-2620.
[cited by applicant]
Myers E.W., et al., “Optimal Alignments in Linear Space,” Cabios, 1988, vol. 4, No. 1, pp. 11-17.
[cited by applicant]
Nada M.H., et al., “Enhancing Adoptive Cancer Immunotherapy with Vγ2Vδ2 T Cells Through Pulse Zoledronate Stimulation,” Journal for Immunotherapy of Cancer, Feb. 21, 2017, vol. 5, No. 1, pp. 1-23, DOI: 10.1186/S40425-01…
[cited by applicant]
Needleman et al. “A General Method Applicable to the Search for Similarities in the Amino Acid Sequence of Two Proteins” Mar. 28, 1970, J. Molecular Biology 48(3):443-453.
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 15/849,062, mailed Feb. 22, 2018, 05 Pages.
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 15/850,937, mailed Feb. 22, 2018, 05 Pages.
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 15/904,131, mailed Jun. 15, 2018, 07 Pages.
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 16/008,991, mailed May 7, 2019, 07 Pages.
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 16/083,384, mailed Mar. 16, 2020, 9 Pages.
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 16/132,247, mailed May 16, 2019, 06 Pages.
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 16/182,443, mailed Dec. 31, 2018,10 Pages.
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 16/530,908, mailed Jun. 1, 2020, 6 Pages.
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 16/563,738, mailed Mar. 12, 2021, 11 Pages.
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 16/614,682, mailed Feb. 28, 2022, 75 Pages.
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 16/943,800, mailed Nov. 25, 2020,08 Pages.
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 17/198,017, mailed Jul. 20, 2021, 7 Pages.
[cited by applicant]
Notice of Allowance for Chinese Application No. 201780017712.6, dated Aug. 25, 2022, 4 Pages. (with English translation).
[cited by applicant]
Notice of Allowance for Japanese Patent Application No. 2018-547354, dated Dec. 17, 2021,6 Pages. (with English translation).
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 14/706,481, mailed Oct. 13, 2019, 05 Pages.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 15/652,080, mailed Nov. 2, 2017, 05 Pages.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 15/849,062, mailed Apr. 26, 2018, 05 Pages.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 15/850,937, mailed Apr. 23, 2018, 05 Pages.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 16/008,991, mailed Aug. 14, 2019, 5 Pages.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 16/083,384, mailed May 18, 2020, 8 Pages.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 16/132,247, mailed Jul. 19, 2019, 05 Pages.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 16/182,443, mailed Jul. 3, 2019, 3 Pages.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 16/182,443, mailed Jun. 18, 2019, 5 Pages.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 16/530,908, mailed Jul. 10, 2020, 05 Pages.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 16/943,800, mailed Feb. 10, 2021,7 Pages.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 16/988,427, mailed Aug. 26, 2022, 5 pages.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 17/198,017, mailed Nov. 3, 2021,6 Pages.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 17/289,653, mailed Jan. 5, 2022, 9 Pages.
[cited by applicant]
Notice of Final Rejection for Japanese Patent Application No. 2018-536892, dated Nov. 16, 2020, 8 Pages.
[cited by applicant]
Notice of Publication in the PCT Application No. PCT/US2021/020721, dated Sep. 10, 2021.
[cited by applicant]
Notice of Reasons for Refusal for japanese Patent Application No. 2018-536892, dated Jul. 11, 2022, 21 Pages.
[cited by applicant]
Notice of Reasons for Refusal for Japanese Patent Application No. 2021-045605, dated Apr. 1, 2022, 5 Pages. (with English translation).
[cited by applicant]
Notice of Reasons for Rejection for Japanese Patent Application No. 2018-547354, mailed Feb. 16, 2021,22 Pages.
[cited by applicant]
Notice of Reasons for Rejection for Japanese Patent Application No. 2021-523916, mailed Jul. 12, 2022, 7 Pages.
[cited by applicant]
Nucleotide: “{Long Control Region} [Human Papillomavirus, type 16, Genomic, 660 nt],” Accession S60559, Publication (online), May 7, 1993 [Retrieved May 9, 2017], 1 Page, XP055455689, Retrieved from URL:https://www.ncbi…
[cited by applicant]
Office Action for Chinese Application No. 202010396594.8, mailed Jan. 15, 2021, 12 Pages.
[cited by applicant]
Office Action for Chinese Patent Application No. 201780017712.6, dated Nov. 3, 2021, 16 Pages. (with English translation).
[cited by applicant]
Office Action for European Patent Application No. 17739028.3, mailed May 22, 2023, 125 pages.
[cited by applicant]
Office Action for Japanese Application No. 2018-536892, mailed Jun. 26, 2020, 07 Pages.
[cited by applicant]
Office Action for Japanese Patent Application No. 2021045605, mailed Nov. 2, 2022, 8 Pages.
[cited by applicant]
Ostertag D., et al., “Brain Tumor Eradication and Prolonged Survival from Intratumoral Conversion of 5-Fluorocytosine to 5-fluorouracil Using a Nonlytic Retroviral Replicating Vector,” Neoro-Oncology, Feb. 2012, vol. 14…
[cited by applicant]
Pauza C.D., et al., “γδ T cells in HIV Disease: Past, Present, and Future,” Frontiers in Immunology, Jan. 30, 2015, vol. 5, No. 687, 12 Pages.
[cited by applicant]
Pauza C.D., et al., “Evolution and Function of the TCR Vgamma9 Chain Repertoire: It's Good to be Public,” Cell Immunology, Jul. 2015, vol. 296, No. 1, pp. 22-30.
[cited by applicant]
Pearson et al. “Improved Tools for Biological Sequence Comparison” Apr. 1988, Proceedings of the National Academy of Sciences of the United States of America 85(8):2444-2448.
[cited by applicant]
Poonia B., et al., “Gamma Delta T Cells From HIV+ Donors Can Be Expanded In Vitro By Zoledronate/Interleukin-2 to Become Cytotoxic Effectors for Antibody-dependent Cellular Cytotoxicity,” Cytotherapy, 2012, vol. 14, No.…
[cited by applicant]
Restriction Requirement for U.S. Appl. No. 16/083,384, mailed Nov. 7, 2019, 8 Pages.
[cited by applicant]
Restriction Requirement for U.S. Appl. No. 16/563,738, mailed Dec. 8, 2020,6 Pages.
[cited by applicant]
Riano F., et al., “Vγ9Vδ2 TCR-activation by Phosphorylated Antigens Requires Butyrophilin 3 A1 (BTN3A1) and Additional Genes on Human Chromosome 6,” European Journal of Immunology, 2014, vol. 44, pp. 2571-2576.
[cited by applicant]
Roden C., et al., “Novel Determinants of Mammalian Primary microRNA Processing Revealed by Systematic Evaluation of Hairpin-Containing Transcripts and Human Genetic Variation,” Cold Spring Harbor Laboratory Press, 2017,…
[cited by applicant]
Sambrook J., et al., “Molecular Cloning: A Laboratory Manual,” 3rd edition, Cold Spring Harbor Laboratory Press, 2000, 2272 Pages.
[cited by applicant]
Sandstorm A., et al., “The Intracellular B30.2 Domain of Butyrophilin 3A1 Binds Phosphoantigens to Mediate Activation of Hu,” Immunity, 2014, vol. 40, No. 4, pp. 490-500, DOI: 10.1016/j.immuni.2014.03.003, ISSN 00047898…
[cited by applicant]
Schiller C.B., et al., “CD19-Specific Triplebody SPM-1 Engages NK and y T Cells for Rapid and Efficient Lysis of Malignant B-Lymphoid Cells,” Oncotarget, 2016, vol. 7(50), pp. 83392-83408.
[cited by applicant]
Second Office Action for Chinese Application No. 201780017712.6, dated Feb. 3, 2021, 10 Pages. (with English translation).
[cited by applicant]
Selbach M., et al., “Widespread Changes in Protein Synthesis Induced by MicroRNAs,” Nature, Sep. 4, 2008, vol. 455, pp. 58-63, DOI: 10.1038/nature07228.
[cited by applicant]
Shalova I.N., et al., “CD16 Regulates TRIF-Dependent TLR4 Response in Human Monocytes and Their Subsets”, The Journal of Immunology, 2012, vol. 188, pp. 3584-3593.
[cited by applicant]
Smith T.F., et al., “Comparison of Biosequences,” Advances in Applied Mathematics, 1981, vol. 2, pp. 482-489.
[cited by applicant]
Third Office Action for Chinese Application No. 201780017712.6, dated May 14, 2021, 8 Pages. (with English translation).
[cited by applicant]
Tian Y., et al., “MicroRNA-30a Promotes Chondrogenic Differentiation of Mesenchymal Stem Cells Through Inhibiting Delta-like 4 Expression,” Life Science, Mar. 1, 2016, vol. 148, 36 Pages, DOI:10.1016/J.LFS.2016.02.031, …
[cited by applicant]
Tokuyama H., et al., “Vy9Vδ2 T Cell Cytotoxicity Against Tumor Cells is Enhanced by Monoclonal Antibody Drugs—Rituximab and Trastuzumab,” International Journal of Cancer, 2008, vol. 122 (11), pp. 2526-2534.
[cited by applicant]
Tolmachov O.E., et al., “Designing Lentiviral Gene Vectors,” Viral Gene Therapy, Jul. 20, 2011, Chapter. 13, 23 Pages, ISBN: 978-953-307-539-6, Retrieved from URL: http://www.intechopen.com/books/viral-gene-therapy/desi…
[cited by applicant]
Tracey A., “Human DNA Sequence from Clone RP1-288M22 on Chromosome 6q 12-13, Complete Sequence,” National Center for Biotechnology, GenBank Entry, Jan. 24, 2013, pp. 1-34, Retrieved from URL:https://www.ncbi.nlm.nih.gov…
[cited by applicant]
Twitty C.G., et al., “Retroviral Replicating Vectors Deliver Cytosine Deaminase Leading to Targeted 5- Fluorouracil-Mediated Cytotoxicity in Multiple Human Cancer Types,” Human Gene Therapy Methods, Feb. 1, 2016, vol. 2…
[cited by applicant]
Ueda M., et al., “CD47-Dependent Molecular Mechanisms of Blood Outgrowth Endothelial Cell Attachment on Cholesterol-Modified Polyurethane,” Biomaterials, Elsevier, Amsterdam, NL, Sep. 1, 2010, vol. 31, No. 25, pp. 6394-…
[cited by applicant]
Wang B., et al., “Kinesin Family Member 11 is a Potential Therapeutic Target and is Suppressed by MicroRNA-30a in Breast Cancer,” Molecular Carcinogenesis, Aug. 2020, vol. 59, No. 8, pp. 908-922.
[cited by applicant]
Wang Y., et al., “Intravenous Delivery of SIRNA Targeting CD47 Effectively Inhibits Melanoma TumorGrmYth and Lung Metastasis,” Molecular Therapy, Oct. 2013, vol. 21, No. 10, pp. 1919-1929.
[cited by applicant]
Wilkin D.J., et al., “Isolation and Sequence of the Human Farnesyl Pyrophosphate Synthetase eDNA,” The Journal of Biological Chemistry, Mar. 15, 1990, vol. 265. No. 8, pp. 4607-4614.
[cited by applicant]
Written Opinion for International Application No. PCT/US2017/013399, mailed May 26, 2017, 8 Pages.
[cited by applicant]
Written Opinion for International Application No. PCT/US2017/021639, mailed Aug. 25, 2017, 7 Pages.
[cited by applicant]
Written Opinion for International Application No. PCT/US2018/037924, mailed Nov. 9, 2018, 11 Pages.
[cited by applicant]
Yang J., et al., “Lentiviral-Mediated Silencing of Famelsy1 Pyrophosphate Synthase through RNA Interference in Mice,” Biomed Research International, 2015, vol. 2015, Article ID. 914026, 07 pages.
[cited by applicant]
Ye Y., et al., “Knockdown of Farnesylpyrophosphate Synthase Prevents Angiotensin II-Medicated Cardiac Hypertrophy,” The International Journal of Biochemistry & Cell Biology, 2010, vol. 42, pp. 2056-2064.
[cited by applicant]
AU; Examination Report issued in Application No. 2021203836 on Jan. 30, 2024.
[cited by applicant]
EP; Search Report issued in Application No. 23199847.7 on Mar. 5, 2024.
[cited by applicant]
{Long control region} [human papillomavirus, type 16, Genomic, 860 nt]; Accession S60559. Publication [online]. May 7, 1993, https://www.ncbi.nlm.nih.gov/nucleotide/237343?report=genbank&log$=nucltop&blast_rank=1&RID=H3…
[cited by applicant]
Bartholome, “Genetics and Biochemistry of the Phenylketonuria-Present State,” Human Genetics, vol. 51(3), pp. 241-245, (1979).
[cited by applicant]
Blau et al., “Phenylketonuria,” The Lancet, vol. 376(9750), pp. 1417-1427, (2010).
[cited by applicant]
Chandler et al., “Vector Design Influences Hepatic Genotoxicity After Adeno-Associated Virus Gene Therapy,” Journal of Clinical Investigation, vol. 125(2), pp. 870-880, (2015).
[cited by applicant]
Charron et al., “Dominant-Negative Interference in the Pahenu2 Mouse Model of PKU: Effectiveness of Vectors Expressing Either Modified Forms of Phenylalanine Hydroxylase (PAH) or Ribozymes Plus a Hardened PAH mRNA,” Mol…
[cited by applicant]
Charron, “Gene Therapy for Phenylketonuria: Dominant-Negative Interference in a Recessive Disease,” Dissertation, University of Florida 2005, http://etd.fcla.edu/UF/UFE0011392/charron_c.pdf>, (retrieved Jul. 26, 2018) (…
[cited by applicant]
Christophersen et al., “A Technique of Transumbilical Portal Vein Catheterization in Adults,” The Archives of Surgery, vol. 95(6), pp. 960-963, (1967). (Abstract Only).
[cited by applicant]
Condiotti et al., “Prolonged Liver-Specific Transgene Expression by a Non-Primate Lentiviral Vector,” Biochemical and Biophysical Research Communications, vol. 320(3), pp. 998-1006, (Jul. 30, 2004).
[cited by applicant]
Daryl S. Schiller, “Parameters Influencing Measurement of the Gag Antigen-Specific T-Proliferative Response to HIV Type 1 Infection,” AIDS Research and Human Retroviruses, vol. 16, No. 3, pp. 259-271, (2000).
[cited by applicant]
Ding et al., “Administration-Route and Gender-Independent Longterm Therapeutic Correction of Phenylketonuria (PKU) in a Mouse Model by Recombinant Adeno-Associated Virus 8 Pseudotyped Vector-Mediated Gene Transfer,” Gen…
[cited by applicant]
Donsante et al., “AAV Vector Integration Sites in Mouse Hepatocellular Carcinoma,” Science, vol. 317(5837, p. 477, (2007).
[cited by applicant]
Eisensmith et al., “Multiple Origins for Phenylketonuria in Europe,” American Journal of Human Genetics, vol. 51(6), pp. 1355-1365, (1992).
[cited by applicant]
EP; Supplementary Search Report in the EP Application No. 18781288.8 dated Dec. 8, 2020.
[cited by applicant]
Fisher et al., “The Inhibition of Phenylalanine and Tyrosine Hydroxylases by High Oxygen Levels,” Journal of Neurochemistry, vol. 19(5), pp. 1359-1365, (1972). (Abstract Only).
[cited by applicant]
Fusetti, et al., “Structure of Tetrameric Human Phenylalanine Hydroxylase and Its Implications for Phenylketonuria,” J. Bio. Chem., vol. 273, No. 27, p. 16962-16967 (1998).
[cited by applicant]
GenBank Accession No. JG619773, MNESC1NG-T3-001_L15_6FEB2009_054 MNESC1NG cell culture from Mahonia nervosa Berberis nervosa cDNA, mRNA sequence, Feb. 13, 2014 (online). [Retrieved on Dec. 5, 2017]. Retrieved from the i…
[cited by applicant]
GenBank Sequence M65141.1 Retrieved from the Internet <URL: https://www.ncbi.ntm.nih.gov/nuccore/M65141.1. Especially Sequence, nt 301-420, (Retrieved Mar. 31, 2019).
[cited by applicant]
Gober et al., “Human T Cell Receptor γδ Cells Recognize Endogenous Mevalonate Metabolites in Tumor Cells,” J. of Experimental Med., Jan. 20, 2003, vol. 197, pp. 163-168.
[cited by applicant]
Grisch-Chan et al., “Low-Dose Gene Therapy for Murine PKU Using Episomal Naked DNA Vectors Expressing PAH from Its Endogenous Liver Promoter,” Molecular Therapy Nucleic Acids, vol. 7, pp. 339-349, (2017).
[cited by applicant]
Guldberg et al., “Aberrant Phenylalanine Metabolism in Phenylketonuria Heterozygotes,” Journal of Inherited Metabolic Disease, vol. 21(4), pp. 365-372, (1998).
[cited by applicant]
Hafid et al., “Phenylketonuria: A Review of Current and Future Treatments,” Translational Pediatrics, vol. 4(4), pp. 304-317, (2015).
[cited by applicant]
Harding et al., “Complete correction of hyperphenylalaninemia following liver-directed, recombinant AAV2/8 vector-medicated gene therapy in murine phenylketonuria”, Gene Ther., Mar. 2006, 13(5):457-462.
[cited by applicant]
Hee Yeon Kim., “Farnesyl diphosphate synthase is important for the maintenance of glioblastoma stemness,” Experimental & Molecular Medicine, (2018).
[cited by applicant]
Ho et al., Translational Pediatrics, 2014, 3(2): 49-62. (Year 2014.
[cited by applicant]
Hong Wang., “Indirect Stimulation of Human V2V2 Cells Through Aleterations in Isoprenoid Metabolism,” The Journal of Immunology, (2011).
[cited by applicant]
Human papillomavirus type 16 (HPV16), complete genome; GenBank: K02718.1; Publication [online], Mar. 18, 1994, https://www.ncbi.nlm.nih.gov/nucleotide/333031?report=genbank&log$=nucltop&blast_rank=22&RID=H3E1THFU014; pp…
[cited by applicant]
JP Office Action in Japanese Application No. 2019-554397, dated Nov. 21, 2022, 8 pages (with English translation).
[cited by applicant]
JP Office Action in Japanese Application No. 2020-518812, dated Aug. 25, 2022, 13 pages (with English translation).
[cited by applicant]
Kaufman et al., “A Model of Human Phenylalanine Metabolism in Normal Subjects and in Phenylketonuric Patients,” Proceedings of the National Academy of Sciences USA, vol. 96(6), pp. 3160-3164, (1999).
[cited by applicant]
Kaufman et al., “Phenylalanine Hydroxylase Activity in Liver Biopsies from Hyperphenylalaninemia Heterozygotes: Deviation from Proportionality with Gene Dosage,” Pediatric Research, vol. 9(8), pp. 632-634, (1975).
[cited by applicant]
Ledley et al., “Retroviral-mediated gene transfer of human phenylalanine hydroxylase into NIH 3T3 and hepatoma cells”, Proceedings of the National Academy of Sciences, vol. 83, No. 2. (Jan. 1, 1986), pp. 409-413, XP0025…
[cited by applicant]
Longo et al., “Single-Dose, Subcutaneous Recombinant Phenylalanine Ammonia Lyase Conjugated with Polyethylene Glycol in Adult Patients with Phenylketonuria: An Open-Label, Multicentre, Phase 1 Dose-Escalation Trial,” Th…
[cited by applicant]
Lu et al., “Anti-sense-Mediated Inhibition of Human Immunodeficiency Virus (HIV) Replication by Use of an HIV Type 1-Based Vector Results in Severely Attenuated Mutants Incapable of Developing Resistance,” Journal of Vi…
[cited by applicant]
Makinen et al., “stable RNA Interference: Comparison of U6 and H1 Promoters in Endothelial Cells and in Mouse Brain,” Journal of Gene Medicine, vol. 8, pp. 433-441, 2006.
[cited by applicant]
Mochizuki et al., “Long-Term Correction of Hyperphenylalaninemia by AAV-Mediated Gene Transfer Leads to Behavioral Recovery in Phenylketonuria Mice,” Gene Therapy, vol. 11(13), pp. 1081-1086, (2004).
[cited by applicant]
Moser et al., “yð T cells: novel initiators of adaptive immunity,” Immunological Reviews, vol. 215, pp. 89-102 (Feb. 2, 2007).
[cited by applicant]
Nault et al., “Adeno-Associated Virus Type 2 as an Oncogenic Virus in Human Hepatocellular Carcinoma,” Molecular & Cellular Oncology, vol. 3(2), p. e1095271, (2016).
[cited by applicant]
Nowacki et al., “The PAH Mutation Analysis Consortium Database: Update 1996,” Nucleic Acid Research, vol. 25(1), pp. 139-142, (Jan. 1, 1997).
[cited by applicant]
Oh et al. “Lentiviral Vector Design Using Alternative RNA Export Elements,” Retrovirology, vol. 4:38, pp. 1-10, (2007).
[cited by applicant]
Oh et al., “Long-Term Enzymatic and Phenotypic Correction in the Phenylketonuria Mouse Model by Adeno-Associated Virus Vector-Mediated Gene Transfer,” Pediatric Research, vol. 56(2), pp. 278-284, (2004).
[cited by applicant]
Oh et al., “Reversal of Gene Expression Profile in the Phenylketonuria Mouse Model After Adeno-Associated Virus Vector-Mediated Gene Therapy,” Molecular Genetics and Metabolism, vol. 86(Supp. 1), pp. S124-132, (2005).
[cited by applicant]
Pan et al., “Biodistribution and Toxicity Studies of VSVG-Pseudotyped Lentiviral Vector After Intravenous Administration in Mice with the Observation of in Vivo Transduction of Bone Marrow,” Molecular Therapy, vol. 6(1)…
[cited by applicant]
PCT; International Preliminary Report on Patentability dated Oct. 8, 2019 in the Application No. PCT/ US2018/025733.
[cited by applicant]
PCT; International Search Report dated Apr. 12, 2019 in Application No. PCT/ US2018/053919.
[cited by applicant]
PCT; International Search Report dated Sep. 24, 2018 in Application No. PCT/US2018/025733.
[cited by applicant]
PCT; Invitation to Pay Additional Fees in Application No. PCT/US2018/053919 dated Feb. 22, 2019.
[cited by applicant]
PCT; Written Opinion dated Apr. 12, 2019 in Application No. PCT/US2018/053919.
[cited by applicant]
PCT; Written Opinion dated Sep. 24, 2018 in Application No. PCT/US2018/025733.
[cited by applicant]
Shedlovsky et al., “Mouse Models of Human Phenylketonuria,” Genetics, vol. 134(4), pp. 1205-1210, (1993).
[cited by applicant]
Stunkel et al., “The Chromatin Structure of the Long Control Region of Human Papillomavirus Type 16 Repress Viral Oncoprotein Expression,” Journal of Virology, vol. 73, No. 3, pp. 1918-1930 (Mar. 1999).
[cited by applicant]
Thompson et al., “Alkylamines cause Vγ9Voδ2 T-cell activation and proliferation by inhibiting the mevalonate pathway,” Blood, Jan. 15, 2006, vol. 107, pp. 651-654.
[cited by applicant]
US Non-Final Office Action in U.S. Appl. No. 16/494,196, dated Dec. 6, 2022, 51 pages.
[cited by applicant]
US Restriction Requirement in U.S. Appl. No. 16/652,867, dated Sep. 9, 2022, 9 pages.
[cited by applicant]
USPTO; Invitation to Pay Additional Fees And, Where Applicable, Protest Fee dated Jul. 17, 2018 in Application No. PCT/US2018/25733.
[cited by applicant]
Wang et al., “Butyrophilin 3A1 Plays an Essential Role in Prenyl Pyrophosphate Stimulation of Human Vg2Vd2 T Cells,” Journal of Immunology, vol. 191(3), pp. 1029-1042, (Jul. 5, 2013).
[cited by applicant]
Yagi et al., “Complete Restoration of Phenylalanine Oxidation in Phenylketonuria Mouse by a Self-Complementary Adeno-Associated Virus Vector,” Journal of Gene Medicine, vol. 13(2), pp. 114-122, (2011).
[cited by applicant]
Yano et al., “Evaluation of Tetrahydrobiopterin Therapy with Large Neutral Amino Acid Supplementation in Phenylketonuria: Effects on Potential Peripheral Biomarkers, Melatonin and Dopamine, for Brain Monoamine Neurotran…
[cited by applicant]
Zhaobing Ding et al., “Liver -Directed, AAV-and Lentivirus-Mediated Gene Therapy in the Phenylketonuria Mouse Model Pah-enu2”, Molecular Therapy, vol. 11, Supp. 1. (May 2005) XP055751452.
[cited by applicant]
Thompson et al., “Alkylamines cause Vγ9Vδ2 T-cell activation and proliferation by inhibiting the mevalonate pathway,” Blood, Jan. 15, 2006, vol. 107, pp. 651-654.
[cited by applicant]
CN Office Action in Chinese Application No. 201880039828.4, dated Mar. 1, 2023, 19 pages (with English translation).
[cited by applicant]
JP Notice of Allowance in Japanese Application No. 2018-536892, dated Mar. 29, 2023, 4 pages (with English translation).
[cited by applicant]
JP Office Action in Japanese Application No. 2019-569226, dated Mar. 20, 2023, 5 pages (with English translation).
[cited by applicant]
JP Office Action in Japanese Application No. 2021-523916, dated Apr. 18, 2023.
[cited by applicant]
JP Office Action in Japanese Application No. 2021-045605, dated Apr. 19, 2023.
[cited by applicant]
CA Office Action in Canadian Application No. 3,011,529, dated Feb. 21, 2023, 7 pages.
[cited by applicant]
JP Office Action in Japanese Application No. 2018-536892, dated Jan. 30, 2023, 4 pages (with English translation).
[cited by applicant]